Spacecraft

GigaDevice Launches GD32F5 Series Cortex®-M33 Core MCUs for High-Performance Applications

Retrieved on: 
Tuesday, April 9, 2024
ECC, GD32, GigaDevice, RWW, SRAM, DSP, OTA, SDRAM, IAR, IEC61508, Communication, SDIO, PLC, GUI, MCU, Software, Power management, OTG, Spacecraft, PWM, Update, Flash, Programmable logic controller, Sensor, Ecosystem, The, Automotive engineering, FMEDA, KEIL, Video game

The GD32F5 series high-performance MCUs offer significantly expanded storage space, excellent processing efficiency, and a wide array of interface options.

Key Points: 
  • The GD32F5 series high-performance MCUs offer significantly expanded storage space, excellent processing efficiency, and a wide array of interface options.
  • The GD32F5 series high-performance MCUs adopt the Arm® Cortex® -M33 core with a maximum operating frequency of 200MHz and a working performance of up to 3.31 CoreMark®/MHz.
  • The GD32F5 series high-performance MCUs are equipped with up to 7.5MB on-chip Flash and 1MB SRAM.
  • GigaDevice provides the new high-performance GD32F5 series MCU with free development environment GD32 IDE, debugging and download tool GD-LINK, and the programming tool GD32 All-In-One Programmer.

Following merger, GCOM and OnCore Consulting to Rebrand as Voyatek

Retrieved on: 
Monday, April 8, 2024
GCOM, Voyager 1, Spacecraft, Public sector

Today, marking the next phase in their integration, the companies announced that they are now Voyatek .

Key Points: 
  • Today, marking the next phase in their integration, the companies announced that they are now Voyatek .
  • GCOM and OnCore employees can still be reached through their legacy email and contact information.
  • The Voyatek brand includes GCOM Software LLC, OnCore Consulting LLC, ASR Analytics, LLC, GANTECH Inc, Qlarion, LLC, and Three Sigma Software LLC.
  • Each company remains a legal entity and their respective contracts and subcontracts will remain as-is.

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Well, Small-cell carcinoma, Therapeutic index, Glomus tumor, Endometrial cancer, Survival, Environment, Service provider, Trichloroethylene, Patient, Primate, Triple-negative breast cancer, Lead, Zymeworks, 3D, Standard of care, Cancer, TAA, Spacecraft, Lung cancer, IND, CD3, DLL3, AACR, Workflow, Antibody, TCE, CD28, Therapy, Stomach, ADC, Vaccine

The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.

Key Points: 
  • The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
  • Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

Retrieved on: 
Monday, April 8, 2024
Sarah Cannon Research Institute, B-cell leukemia, AML, B-ALL, Patient, Webcast, Neoplasm, Acute myeloid leukemia, Cancer, Syndrome, Spacecraft, Camptothecin, AACR, DLT, PALO, Antibody, Drug development, Safety, Infrared spectroscopy correlation table, MDS, Therapy, ADC, Drug resistance, Pharmaceutical industry

PALO ALTO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • We are still in dose escalation and are starting to see tumor reduction after only two doses.
  • The study's main objective is to determine a safe dose and schedule for VIP236 for further clinical development.
  • As the study progresses through the dose escalation, Vincerx will present additional Phase 1 data for VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
  • An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Toxicity, Therapeutic index, KOSDAQ, Partnership, MMAE, Breast, Cancer, Spacecraft, CDX, AACR, PDX, Neoplasm, Pharmacokinetics, LCB, EC50, ADC

The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.

Key Points: 
  • The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
  • The presentation includes data demonstrating LNCB74’s high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers.
  • LNCB74 was shown to specifically bind to B7-H4 expressing tumor cells and was rapidly internalized in a target-dependent manner.
  • “These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications.

Araris Biotech AG Presents Data on Novel Antibody-Drug Conjugates at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Spacecraft, ADC, AACR, San Diego Convention Center, Vaccine

AU ZH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the company will deliver two poster presentations, including one late-breaking poster, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.

Key Points: 
  • AU ZH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the company will deliver two poster presentations, including one late-breaking poster, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.
  • The presentations highlight preclinical data on two novel dual TOP1i antibody-drug conjugates (ADCs) generated using Araris’ proprietary ADC conjugation technology and linker platform.
  • “The preclinical data highlighted in our presentations at this year’s AACR meeting demonstrate the potential of novel dual TOP1i ADCs, generated using two TOP1i payloads, each with differing properties that help improve efficacy and tolerability of the ADC,” said Philipp Spycher, Ph.D., co-founder and chief scientific officer of Araris Biotech AG.
  • “We’re excited by the promise of combining these payloads in various ADCs, along with a stable attachment using our conjugation technology, to create therapeutic options with potentially superior inhibition of tumor growth for patients.”
    Presentation details are summarized below:
    Abstract Title: Novel dual TOP1i ADC inducing superior tumor growth inhibition at low-drug load vs. trastuzumab deruxtecan
    In mouse PK studies, the excellent in vitro stability of the ADC was confirmed with no signs of payload loss or linker-cleavage, and the ADC showed mAb-like exposure to maximize payload delivery
    In head-to-head study vs T-DXd using a HER2-expressing breast cancer model, Araris’ ADC showed superior anti-tumor efficacy compared to T-DXd
    Generated an anti-NaPi2b ADC with two TOP1i payloads that have different properties, designed to maximize tumor-specific activity
    Showed excellent stability in mouse and human sera without payload deconjugation or linker cleavage, as well as stability in circulation, high anti-tumor activity, and mAb-like PK exposure to maximize payload delivery

Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit

Retrieved on: 
Friday, April 5, 2024
Spacecraft, Antibody, ADC, Cleveland Clinic, Conjugation, JPMorgan Chase, Antibody-drug conjugate

Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.

Key Points: 
  • Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.
  • "We are thrilled to be selected as a finalist for this prestigious summit," said Dr. Seah Lim , Founder and CEO of Medicovestor.
  • The Life Sciences Innovation Summit, hosted by JP Morgan Asset Management, serves as a prestigious platform for leading innovators, investors, and industry experts to explore cutting-edge advancements in healthcare and life sciences.
  • During the summit, Medicovestor aims to share insights into its ADC platform development, preclinical progress, and future prospects.

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, AstraZeneca, Merck, Cancer, Doctor of Philosophy, Spacecraft, B7-H4, Antibody, Johnson & Johnson, Immunotoxin, CSO, MedImmune

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
  • As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
  • “We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug conjugates,” said Solomon Langermann, PhD, NextCure’s chief scientific officer.
  • “Rakesh is a world authority on ADCs and has an incredible record of researching and developing them.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 4, 2024
Spacecraft, MRSN, Employment, RSU, Cancer, Therapy

CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in March 2024.

Key Points: 
  • CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in March 2024.
  • The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2024, subject to the employee’s continued service with Mersana on each such vesting date.
  • The RSU award is subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of an RSU agreement covering the grant.

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Retrieved on: 
Wednesday, April 3, 2024
Ovarian cancer, BofA Securities, PIN, U.S. FDA, Shearman, Webcast, Patient, Fast Track, Goldman Sachs, Morgan Stanley, LLP, Acquisition, Cancer, Spacecraft, Cooley LLP, DKK, Shearman & Sterling, ADC, USD, Law, Food, Pharmaceutical industry

Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).

Key Points: 
  • Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).
  • The transaction will further broaden Genmab’s mid- to late-stage clinical pipeline and strengthen and complement Genmab’s already validated suite of proprietary technology platforms.
  • The addition of Rina-S to Genmab’s portfolio will enable Genmab to deepen its presence in the gynecologic oncology space and establish a firm foundation in solid tumors.
  • Based on the data from the ongoing Phase 1/2 clinical trial Genmab intends to broaden the development plans for Rina-S within ovarian cancer and other FRα-expressing solid tumors.